Study guide
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023
Key Takeaways Explain This Topic AI
The Controlled Substances Act (CSA) establishes five schedules based on abuse potential, accepted medical utility, and physical or psychological dependence liability.
Schedule II substances (e.g., methadone, oxycodone, fentanyl, amphetamines) permit zero refills and are subject to strict 30-day limits and mandatory electronic prescribing.
The landmark Mainstreaming Addiction Treatment (MAT) Act of 2023 completely eliminated the DATA 2000 X-waiver, enabling any DEA-registered prescriber with Schedule III authority to prescribe buprenorphine for OUD without patient caps.
The Medication Access and Training Expansion (MATE) Act mandates an 8-hour, one-time training on substance use disorders for all initial and renewing DEA registrations.
The MAT Act did NOT deregulate methadone: methadone maintenance and detoxification for Opioid Use Disorder remain restricted exclusively to SAMHSA-certified Opioid Treatment Programs (OTPs).
Last updated: November 2026
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023
Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) specializing in addictions must master federal controlled substance scheduling criteria, DEA registration requirements, state-level prescriptive authority variations, and landmark federal legislation governing opioid use disorder pharmacotherapy to maintain strict regulatory compliance while optimizing patient access.
1. Controlled Substances Act (CSA) Statutory Architecture
Enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, the Controlled Substances Act (CSA) (21 U.S.C. § 801 et seq.) establishes the legal foundation for the federal regulation of psychotropic and dependence-inducing chemical entities. The legislation places all regulated substances into one of five distinct "schedules" based on three statutory determinations:
Potential for abuse: The drug's affinity for recreational misuse, diversion, self-administration without medical oversight, and capacity to produce euphoria or intoxication.
Currently accepted medical use: Scientific and clinical consensus, established by the Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA), regarding the substance's therapeutic safety and efficacy in the United States.
Dependence liability: The propensity of the substance to produce physiological neuroadaptation (physical dependence, tolerance, withdrawal) and psychological craving or compulsive substance-seeking behavior. CSA Scheduling Matrix: Regulatory Control vs. Clinical Utility
- Schedule I ──► [Extreme Abuse Potential | NO Accepted Medical Use] ──► Research/IND Only
- Schedule II ──► [High Abuse Potential | Accepted Medical Use] ──► Severe Control (No Refills)
- Schedule III ──► [Moderate Abuse Potential| Accepted Medical Use] ──► Max 5 Refills / 6 Months
- Schedule IV ──► [Low Abuse Potential | Accepted Medical Use] ──► Max 5 Refills / 6 Months
- Schedule V ──► [Lowest Abuse Potential | Accepted Medical Use] ──► Standard Prescription / OTC
- 2. DEA Schedule Classifications, Prescribing Rules & Clinical Examples
Federal statutes establish distinct clinical governance, storage, inventory, and prescription transmission requirements across the five schedules.
Schedule Abuse Potential & Dependence Liability Accepted Medical Use Prescribing & Refill Limitations Representative Clinical Entities
Schedule I High potential for abuse; severe psychological and physical dependence liability; lack of accepted safety under medical supervision. None in the United States. No accepted clinical prescription utility. Prescriptions prohibited . Accessible exclusively under DEA Schedule I research registrations and FDA Investigational New Drug (IND) protocols. Heroin, lysergic acid diethylamide (LSD), mescaline, peyote, psilocybin, methylenedioxymethamphetamine (MDMA), methaqualone, illicit synthetic cannabinoids/cathinones, bath salts. (Marijuana remains Schedule I federally except marijuana in an FDA-approved drug product or subject to a state medical marijuana license, which moved to Schedule III on April 28, 2026; broader rescheduling is pending.)
Schedule II High potential for abuse; abuse may lead to severe psychological or physical dependence; profound physiological tolerance. Yes ; accepted medical use with severe restrictions. NO REFILLS permitted. Maximum 30-day supply per individual prescription (prescribers may issue up to three sequential 30-day prescriptions with 'do not fill before' instructions for a 90-day maximum). Mandatory Electronic Prescribing of Controlled Substances (EPCS). Verbal emergency orders permitted only for immediate treatment duration, with a written/electronic script provided within 7 days. Methadone, oxycodone, morphine, hydromorphone, oxymorphone, fentanyl, hydrocodone combination products (rescheduled from III to II in 2014), tapentadol, amphetamine salts (Adderall), dextroamphetamine, lisdexamfetamine (Vyvanse), methylphenidate (Ritalin/Concerta), cocaine (topical anesthetic), pentobarbital.
Schedule III Abuse potential less than Schedules I and II; abuse may lead to moderate or low physical dependence or high psychological dependence. Yes ; accepted medical use. Prescriptions expire 6 months after issuance. Maximum of 5 refills permitted within the 6-month period. Oral or facsimile orders permitted. Buprenorphine (Suboxone, Subutex, Sublocade, Brixadi), ketamine, dronabinol oral capsules (Marinol), anabolic steroids (testosterone, oxandrolone), acetaminophen with codeine (Tylenol #3, up to 90 mg codeine per dosage unit), butalbital compounds with aspirin.
Schedule IV Low potential for abuse relative to substances in Schedule III; abuse may lead to limited physical dependence or psychological dependence. Yes ; accepted medical use. Prescriptions expire 6 months after issuance. Maximum of 5 refills permitted within the 6-month period. Oral or electronic orders permitted. Benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam, temazepam, chlordiazepoxide), non-benzodiazepine Z-hypnotics (zolpidem, zaleplon, eszopiclone), tramadol, phenobarbital, carisoprodol (Soma), modafinil, suvorexant, lemborexant.
Schedule V Low potential for abuse relative to Schedule IV; contains limited quantities of certain narcotics; low physical and psychological dependence liability. Yes ; accepted medical use. May be refilled as authorized by the prescriber for up to 1 year from issuance (governed by state law). In select jurisdictions, non-prescription dispensing permitted with pharmacist sign-off. Pregabalin (Lyrica), diphenoxylate with atropine (Lomotil), lacosamide (Vimpat), codeine-containing cough preparations (promethazine with codeine, Robitussin AC, containing ≤200 mg codeine per 100 mL or per 100 g).
3. Prescriptive Authority Mechanics: DEA Registration & State Scope of Practice
Prescriptive authority for controlled substances is a dual federal-state construct. An APRN cannot prescribe controlled substances without holding both independent or collaborative state licensure and a federal DEA registration.
State Practice Environment vs. Federal Authority
Full Practice Authority (FPA): The APRN evaluates patients, diagnoses, prescribes controlled substances, and manages therapies independently under the exclusive licensure authority of the State Board of Nursing without requiring a physician collaborative agreement or supervision.
Reduced / Restricted Practice: State law mandates a formalized collaborative practice agreement (CPA), written protocol, or physician delegation/supervision to prescribe controlled substances, often imposing specific formulary exclusions or capping Schedule II durations (e.g., 7-day limit for initial acute Schedule II opioid prescriptions).
DEA Precedence Rule: Federal DEA registration confers prescribing authority only up to the maximum limit authorized by state law . If state scope of practice prohibits an APRN from prescribing Schedule II agents, a federal DEA Schedule II registration cannot override that state restriction.
Electronic Prescribing of Controlled Substances (EPCS)
The DEA promulgated regulations establishing EPCS to curb diversion, prescription forgery, and fraudulent alteration:
Two-Factor Authentication (2FA): Clinicians must utilize two of three authentication factors prior to signing: something you know (password/PIN), something you have (hardware token, cryptographically secured smartphone authenticator), or something you are (biometric fingerprint or facial scan).
Audit Trails & Security: Electronic Health Record (EHR) systems must undergo third-party certification confirming tamper-evident logging, logical access controls, and daily prescription reconciliation.
4. The Mainstreaming Addiction Treatment (MAT) Act of 2023 Evolution of Federal Buprenorphine Prescribing Authority:
- [DATA 2000 Enacted]
- │ • Required 8-24 hours training
- │ • Separate 'X-Waiver' DEA registration
- │ • Strict patient caps (30/100/275)
- ▼
- [CARA 2016 & SUPPORT Act 2018]
- │ • Expanded X-waiver eligibility to NPs, CNSs, CRNAs, CNMs, PAs
- │ • Maintained burdensome registration barriers & audit liability
- ▼
- [MAT Act of 2023 (P.L. 117-328)] ──► Enacted Dec 29, 2022
- COMPLETELY ELIMINATED THE X-WAIVER!
- ZERO patient caps
- Buprenorphine integrated into standard Schedule III authority
- Legislative Background & Elimination of the X-Waiver
For over two decades, the Drug Addiction Treatment Act of 2000 (DATA 2000) (21 U.S.C. § 823(g)(2)) restricted office-based buprenorphine prescribing for Opioid Use Disorder (OUD) to clinicians who applied for and received an "X-waiver" (an identification number starting with the letter 'X' issued alongside their standard DEA registration). Prescribers were subjected to mandatory training hours, invasive DEA compliance inspections, and strict statutory patient limits:
Year 1: 30-patient cap.
Year 2: Permitted expansion to 100 patients upon formal notification.
Subsequent Years: Permitted expansion to 275 patients under strict qualifying criteria (e.g., board certification or specialized practice settings).
On December 29, 2022 , President Biden signed into law the Consolidated Appropriations Act of 2023 (Public Law 117-328) , which incorporated the Mainstreaming Addiction Treatment (MAT) Act (Section 1262) . The MAT Act decisively dismantled the DATA 2000 apparatus:
Complete Abolition of the X-Waiver: The requirement for an X-waiver was entirely expunged from federal law effective immediately.
Universal Schedule III Authority: Any healthcare provider (APRN, physician, PA) possessing a standard DEA registration with Schedule III authority can now prescribe buprenorphine for the treatment of OUD within their ordinary scope of clinical practice.
Elimination of Patient Limits: Federal statutory patient limits (30, 100, 275) were repealed in their entirety. Clinicians may treat as many patients with buprenorphine as their clinical capacity and standard of care allow.
Removal of Special Notice Requirements: Clinicians are no longer required to submit a Notice of Intent (NOI) to SAMHSA or undergo specialized DEA record inspections unique to addiction pharmacotherapy.
5. The Medication Access and Training Expansion (MATE) Act
Enacted concurrently under Section 1263 of the Consolidated Appropriations Act of 2023, the Medication Access and Training Expansion (MATE) Act established a new federal educational baseline to ensure all DEA-registered clinicians possess core competencies in substance use disorder identification and treatment.
Mandatory Educational Criteria
Effective June 27, 2023 , all healthcare providers applying for an initial DEA registration or submitting a three-year DEA registration renewal must attest to having completed at least 8 hours of qualifying training on the prevention, screening, and treatment of opioid and other substance use disorders, including the clinical management of patients with co-occurring pain and mental health conditions.
Pathways to Satisfy the MATE Act Requirement
Prescribers can fulfill the 8-hour requirement through several recognized pathways:
Addiction Board Certification: Clinicians certified in addictions nursing (e.g., CARN-AP , CARN) by the Addictions Nursing Certification Board (ANCB), or certified by the American Board of Addiction Medicine (ABAM) or American Board of Preventive Medicine (ABPM), automatically fulfill the requirement.
Accredited Continuing Education: Completion of 8 cumulative hours of accredited coursework delivered by qualifying organizations, including the American Association of Nurse Practitioners (AANP), American Nurses Credentialing Center (ANCC), American Society of Addiction Medicine (ASAM), American Academy of Addiction Psychiatry (AAAP), or AMA-accredited CME providers.
Prior DATA 2000 Training: Any clinician who previously completed the 8-hour or 24-hour training required under DATA 2000 has satisfied the MATE Act in perpetuity.
Health Professional School Curriculum: Graduation within 5 years from an accredited nursing, medical, or physician assistant school that incorporated at least 8 hours of SUD and pain management coursework into its core didactic curriculum.
Important Regulatory Note: The MATE Act training requirement is a one-time attestation . Once satisfied, the clinician is not required to complete an additional 8 hours for subsequent DEA renewal cycles, though ongoing continuing education is strongly recommended for advanced practice certification maintenance.
6. Methadone Dispensing Restrictions & 42 CFR Part 8
While the MAT Act eliminated restrictions on office-based buprenorphine, it did not alter federal statutes governing methadone for the treatment of Opioid Use Disorder. Federal Opioid Treatment Architecture:
- [Opioid Use Disorder Pharmacotherapy]
- │
- ┌───────────┴───────────┐
- ▼ ▼
- [Buprenorphine for OUD] [Methadone for OUD]
- Office-Based (OBOT) • SAMHSA-Certified OTPs ONLY
- Standard Schedule III DEA • 42 CFR Part 8 Regulations
- Retail Pharmacy Fill • Daily Observed Dosing / Take-Homes
- No Patient Caps • CANNOT be dispensed at Retail Pharmacies
- The Strict Opioid Treatment Program (OTP) Boundary
Under federal law (21 U.S.C. § 823(g)(1) and 42 CFR Part 8 ), methadone maintenance and detoxification treatment for OUD may only be administered or dispensed by SAMHSA-certified, DEA-registered Opioid Treatment Programs (OTPs) .
Prohibition on Retail Pharmacy Dispensing for OUD: Retail community pharmacies are legally prohibited from dispensing methadone for the treatment of OUD. An outpatient prescription written for methadone containing instructions such as "take 80 mg daily for opioid dependence" cannot be filled by a retail pharmacy.
Analgesic Exception: Methadone remains an FDA-approved Schedule II analgesic. APRNs and physicians holding valid Schedule II authority may legally prescribe methadone in outpatient office settings exclusively for severe, chronic, intractable pain . When prescribing methadone for analgesia, prescribers must explicitly document the pain indication in the medical record and on the face of the prescription (e.g., "methadone 10 mg TID for intractable neuropathic cancer pain") to distinguish it from prohibited OUD therapy.
The 'Three-Day Rule' (21 CFR § 1306.07(b)): A non-OTP practitioner who is not licensed as an OTP may administer (but not prescribe) narcotic drugs (such as methadone or buprenorphine) to an individual for the purpose of relieving acute withdrawal symptoms while arranging for the patient's referral to an addiction treatment program. Conditions:
Maximum treatment duration is 72 hours (3 days) .
Only one day's supply may be administered at a time.
The medication must be directly administered in person; no prescriptions may be issued.
The 72-hour period cannot be renewed or extended.
Inpatient Hospitalization Exception (21 CFR § 1306.07(c)): When a patient with opioid dependence is admitted to an acute care general hospital for a primary medical or surgical condition other than addiction (e.g., endocarditis, osteomyelitis, polytrauma), hospital clinicians may legally administer methadone or buprenorphine to maintain the patient or manage withdrawal as an incidental part of their inpatient medical stabilization.